WT1 peptide immunotherapy for cancer in children and young adults - PubMed (original) (raw)

Clinical Trial

doi: 10.1002/pbc.22522.

Affiliations

• PMID: 20582983
• DOI: 10.1002/pbc.22522

Clinical Trial

WT1 peptide immunotherapy for cancer in children and young adults

Yoshiko Hashii et al. Pediatr Blood Cancer. 2010 Aug.

Abstract

Wilms tumor gene (WT1) can be overexpressed in childhood cancers. We evaluated the efficacy of WT1 vaccination for five children with solid cancer or acute leukemia. WT1 vaccine was administered to HLA-A*2402-positive patients with WT1-overexpressing residual tumor despite prior conventional treatment. One patient showed complete response and one patient showed stable disease according to the Response Evaluation Criteria in Solid Tumors; the remaining three showed progressive disease. Treatment-related adverse effects were limited to local injection site erythema. These results suggest that WT1 vaccination has therapeutic potential, but any beneficial effect may be insufficient in the presence of gross residual disease.

(c) 2010 Wiley-Liss, Inc.

PubMed Disclaimer

Similar articles

• WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
  Ohta H, Hashii Y, Yoneda A, Takizawa S, Kusuki S, Tokimasa S, Fukuzawa M, Tsuboi A, Murao A, Oka Y, Oji Y, Aozasa K, Nakatsuka S, Sugiyama H, Ozono K. Ohta H, et al. Pediatr Hematol Oncol. 2009 Jan;26(1):74-83. doi: 10.1080/08880010802435500. Pediatr Hematol Oncol. 2009. PMID: 19206012
• [WT1 peptide-based immunotherapy].
  Sugiyama H. Sugiyama H. Nihon Rinsho. 2005 Jun;63(6):1101-9. Nihon Rinsho. 2005. PMID: 15948398 Review. Japanese.
• [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
  Gu WY, Cao XS, Qiu GQ, Chen ZX, Sheng LX, Xie XB, He J, Cen JN, Shen HL. Gu WY, et al. Zhonghua Yi Xue Za Zhi. 2005 Dec 28;85(49):3475-80. Zhonghua Yi Xue Za Zhi. 2005. PMID: 16686063 Chinese.
• Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
  May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. May RJ, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. doi: 10.1158/1078-0432.CCR-07-0708. Clin Cancer Res. 2007. PMID: 17671141
• [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
  Hashimoto N, Tsuboi A, Chiba Y, Izumoto S, Oka Y, Yoshimine T, Sugiyama H. Hashimoto N, et al. Brain Nerve. 2009 Jul;61(7):805-14. Brain Nerve. 2009. PMID: 19618858 Review. Japanese.

Cited by

• Administration of a glypican-3 peptide increases the infiltration and cytotoxicity of CD8+ T cells against testicular yolk sac tumor, associated with enhancing the intratumoral cGAS/STING signaling.
  Zhao J, Qin L, He G, Xie T, Hu G, Wang F, Zhong H, Zhu J, Xu Y. Zhao J, et al. Cancer Med. 2023 Dec;12(23):21293-21307. doi: 10.1002/cam4.6605. Epub 2023 Nov 20. Cancer Med. 2023. PMID: 37986544 Free PMC article.
• Wilms' Tumor 1 (WT1): The Vaccine for Cancer.
  Hein KZ, Yao S, Fu S. Hein KZ, et al. J Immunother Precis Oncol. 2020 Nov 12;3(4):165-171. doi: 10.36401/JIPO-20-12. eCollection 2020 Nov. J Immunother Precis Oncol. 2020. PMID: 35665371 Free PMC article. Review.
• Immunotherapy Associated Neurotoxicity in Pediatric Oncology.
  Shalabi H, Nellan A, Shah NN, Gust J. Shalabi H, et al. Front Oncol. 2022 Feb 21;12:836452. doi: 10.3389/fonc.2022.836452. eCollection 2022. Front Oncol. 2022. PMID: 35265526 Free PMC article. Review.
• Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies.
  Olsen HE, Lynn GM, Valdes PA, Cerecedo Lopez CD, Ishizuka AS, Arnaout O, Bi WL, Peruzzi PP, Chiocca EA, Friedman GK, Bernstock JD. Olsen HE, et al. Neurooncol Adv. 2021 Feb 11;3(1):vdab027. doi: 10.1093/noajnl/vdab027. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 33860227 Free PMC article. Review.
• Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1-specific CD8+ T cells.
  Pearson FE, Tullett KM, Leal-Rojas IM, Haigh OL, Masterman KA, Walpole C, Bridgeman JS, McLaren JE, Ladell K, Miners K, Llewellyn-Lacey S, Price DA, Tunger A, Schmitz M, Miles JJ, Lahoud MH, Radford KJ. Pearson FE, et al. Clin Transl Immunology. 2020 Jun 12;9(6):e1141. doi: 10.1002/cti2.1141. eCollection 2020. Clin Transl Immunology. 2020. PMID: 32547743 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program